

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6049538

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
XIAO MENG	04/27/2018
FENGLAI SUN	04/27/2018
JINGYANG ZHU	04/27/2018
RECEIVING PARTY DATA	
Name:	SHANGHAI SYNTHEALL PHARMACEUTICAL CO., LTD.
Street Address:	9 YUEGONG ROAD
Internal Address:	JINSHAN DISTRICT
City:	SHANGHAI
State/Country:	CHINA
Postal Code:	201507
PROPERTY NUMBERS Total: 1	
Property Type	Number
PCT Number:	US2018034566
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650)493-9300
Email:	saba.smith@wsgr.com, jhuddleston@wsgr.com, patentdocket@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	56054-709.601
NAME OF SUBMITTER:	SABA SMITH
SIGNATURE:	/Saba Smith/
DATE SIGNED:	04/07/2020
Total Attachments: 2	
source=56054-709 Meng, Sun, and Zhu to Shanghai SynTheAll Pharmaceutical Co., Ltd#page1.tif	
source=56054-709 Meng, Sun, and Zhu to Shanghai SynTheAll Pharmaceutical Co., Ltd#page2.tif	

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Shanghai SynTheAli Pharmaceutical Co., Ltd., having a place of business at 9 Yuegong Road, Jinshan District, Shanghai, 201507, China, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. PCT/US2018/034566, entitled "METHODS OF MAKING AND USING PDE9 INHIBITORS" filed on May 25, 2018 which claims priority to U.S. 62/511,367 filed May 26, 2017.

2. The entire worldwide right, title, and interest in and to:
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not


Title: METHODS OF MAKING AND USING PDE9 INHIBITORS
Filed: May 25, 2018
Application No.: PCT/US2018/034566

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.


INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.


This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date Apr. 27. 2018 Signature 
Name Xiao Meng

Date Apr. 27. 2018 Signature 
Name Fenglai Sun

Date April 27. 2018 Signature 
Name Jingyang Zhu

The undersigned acknowledges and accepts this assignment on behalf Shanghai SynTheAll Pharmaceutical Co., Ltd.

Date Apr. 28. 2018 Signature 
Authorized Representative of Shanghai SynTheAll
Pharmaceutical Co., Ltd.